57,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Oxidative stress is the cellular imbalance of pro-oxidants (promoting cell death) and antioxidants (facilitating cell survival and chemotharapy/radiotherapy resistance). However, it remains unexplored whether endocrine or anti-EGFR resistance also associates with altered redox balance. In this project, redox balance was examined using in vitro human resistant breast cancer models TAMR, FASR, X-MCF and NEW DUBS, comparing with responsive w/tMCF7 cells using microarray analysis, PCR, and TAC, ROS, or MTT assays. Significantly increased antioxidant levels were observed in all resistant models,…mehr

Produktbeschreibung
Oxidative stress is the cellular imbalance of pro-oxidants (promoting cell death) and antioxidants (facilitating cell survival and chemotharapy/radiotherapy resistance). However, it remains unexplored whether endocrine or anti-EGFR resistance also associates with altered redox balance. In this project, redox balance was examined using in vitro human resistant breast cancer models TAMR, FASR, X-MCF and NEW DUBS, comparing with responsive w/tMCF7 cells using microarray analysis, PCR, and TAC, ROS, or MTT assays. Significantly increased antioxidant levels were observed in all resistant models, perhaps limiting pro-oxidant increases to maintain cell survival. Antioxidants were also significantly induced by antihormones in w/tMCF7 cells that may limit apoptosis with early treatment. Future deciphering and depletion of antioxidants could feasibly block cell survival in multiple resistant states. Resistant cells may be particularly sensitive to agents inducing excessive oxidative stress. Feasibility of agents influencing redox remains complex, However, new findings and concepts emerging from this thesis are worthy of future exploration for potential treatments.
Autorenporträt
Born in 1983, Maryam grew up in Cardiff, Wales. She obtained a first class honours degree in Biology and went on to research the molecular biology of Breast Cancer. Out of the laboratory and into the clinic, Maryam is now working with patients on their quality of life with the European Organisation for the Treatment of Cancer at Bristol University